Price Alert: Shares of Regenxbio (RGNX) Trade 6.23% Higher at Midday June 22

Equities Staff  |

Today Regenxbio Inc (NASDAQ: RGNX) is trading 6.23% higher.

The latest price, as of 12:09:35 est, was $23.33. Regenxbio has risen $1.37 over the previous day’s close.

237,515 shares have been traded today.

As of the previous close, Regenxbio has a YTD change of 32.72%. The company anticipates its next earnings on 2022-08-09.

For technical charts, analysis, and more on Regenxbio visit the company profile.

About Regenxbio Inc

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

To get more information on Regenxbio Inc and to follow the company's latest updates, you can visit the company's profile page here: Regenxbio Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content